logo-loader

Small-Cap Snapshot: Yelp shares climb despite losing bid to join case against Google

Last updated: 12:25 19 Dec 2018 EST, First published: 12:04 19 Dec 2018 EST

stock market trading floor

Yelp Inc (NYSE:YELP) stock headed higher on investor interest despite losing a bid to intervene in the case filed against Alphabet' Inc's Google (NASDAQ:GOOG) by British price comparison shopping site Foundem. Yelp and Consumer Watchdog had jointly sought to join the court proceedings so their rights and interests would be covered by the final ruling in the case. The General Court, however, supported Google's argument against Yelp's intervention, saying that while it took part as an interested third party in the EU investigation, it runs a different business from Google.

Yelp shares rose almost 4% to $35.13.

Surface Oncology Inc (NASDAQ:SURF) stock crumbled after the company said it was pulling back investments on its lead drug. The shuffling of its priorities will give Surface Oncology a longer cash runway which will be tended into 2021. Phase 1 clinical work for the company’s Novartis-partnered CD73 program, NZV930, is ongoing, said the company.

Surface Oncology stock dove 33.6% to $4.92.

Rent-A-Center Inc (NASDAQ:RCII) stock popped after the company terminated its acquisition by Vintage Capital Management LLC. Rent-A-Center was acquired by a Vintage affiliate in a $1.37 billion deal that was announced in June. Rent-A-Center said it terminated the merger deal as its current financial and operational performance led it to decide not to extend the end date of the deal and exercise its right to end the deal. The company also said it notified Vintage of its obligation to pay a $126.5 million "reverse breakup fee."

Rent-A-Center stock increased 12% to $14.60.

READ: Surface Oncology pares lead program after tracking low-dose toxicity in drug targeting CD47 protein

Jabil Inc (NYSE:JBL) stock climbed after reporting solid first-quarter earnings. The company also beat fourth-quarter earnings and revenue as it maintained a steady drumbeat in executing its business operations.Jabil said it expects adjusted fiscal second-quarter earnings of $0.51-$0.71 cents a share on sales of $5.8 billion to $6.4 billion.

Jabil stock went up nearly 8% to $23.98%.

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) shares are nearly flat after surging earlier on a joint venture in China, Korea and the territories of Macau and Hong Kong. Ziopharm will license the rights to the Eden BioCell for third-generation Sleeping Beauty-generated CAR-T therapies. Eden BioCell will be owned 50-50 by Ziopharm and its partner TriArm.

ZIOPHARM stock was steady at $2.43.

Contact Rene Pastor by rene.pastor@proactiveinvestors.com

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

4 hours, 48 minutes ago